The Diagnostic role of Soluble (sAxl) Level in Patients with Hepatocellular Carcinoma compared to Alpha-fetoprotein
El Lehleh, A., Abd Elbary, N., Elzayat, R., El-Gazzarah, A., Elabd, N. (2020). The Diagnostic role of Soluble (sAxl) Level in Patients with Hepatocellular Carcinoma compared to Alpha-fetoprotein. EKB Journal Management System, 10(2), 213-225. doi: 10.21608/aeji.2020.28650.1074
Ayman M El Lehleh; Nasser M Abd Elbary; Reham Elzayat; Ahmed R El-Gazzarah; Naglaa S Elabd. "The Diagnostic role of Soluble (sAxl) Level in Patients with Hepatocellular Carcinoma compared to Alpha-fetoprotein". EKB Journal Management System, 10, 2, 2020, 213-225. doi: 10.21608/aeji.2020.28650.1074
El Lehleh, A., Abd Elbary, N., Elzayat, R., El-Gazzarah, A., Elabd, N. (2020). 'The Diagnostic role of Soluble (sAxl) Level in Patients with Hepatocellular Carcinoma compared to Alpha-fetoprotein', EKB Journal Management System, 10(2), pp. 213-225. doi: 10.21608/aeji.2020.28650.1074
El Lehleh, A., Abd Elbary, N., Elzayat, R., El-Gazzarah, A., Elabd, N. The Diagnostic role of Soluble (sAxl) Level in Patients with Hepatocellular Carcinoma compared to Alpha-fetoprotein. EKB Journal Management System, 2020; 10(2): 213-225. doi: 10.21608/aeji.2020.28650.1074

The Diagnostic role of Soluble (sAxl) Level in Patients with Hepatocellular Carcinoma compared to Alpha-fetoprotein

Afro-Egyptian Journal of Infectious and Endemic Diseases
Article 22, Volume 10, Issue 2, June 2020, Page 213-225  XML PDF (855.13 K)
Document Type: Original Article
DOI: 10.21608/aeji.2020.28650.1074
View on SCiNiTO View on SCiNiTO
Authors
Ayman M El Lehlehorcid 1; Nasser M Abd Elbary2; Reham Elzayatorcid 3; Ahmed R El-Gazzarahorcid 1; Naglaa S Elabd email orcid 1
1Department of Tropical Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt.
2Department of Clinical Oncology, Faculty of Medicine, Menoufia University, Menoufia, Egypt.
3Department of Clinical pathology, Faculty of Medicine, Menoufia University, Menoufia, Egypt.
Abstract
Background and Aim: Hepatocellular carcinoma deemed for the plurality of primary liver cancers. Malignancy of the liver is the fourth most popular etiology of cancer mortality worldwide. The high mortality of HCC cases is linked to the delay in diagnosis. Aberrant expression of Axl frequently occurs in many malignancies and is critical for promoting cell proliferation, migration, angiogenesis and metastasis. Axl deregulated activation or expression is linked to resistance to targeted cancer therapies. we aimed to to clear up the diagnostic role of sAXL in HCC patients.
Methods: Study included 90 participants; 40 HCC patients on top of liver cirrhosis, 30 patients with liver cirrhosis and twenty healthy subjects (controls). CBC, liver and kidney function tests, alpha-fetoprotein, abdominal ultrasound and triphasic CT were performed. sAxl was assessed by ELISA.
Results: sAxl was considerably higher in HCC patients than in cirrhotic and control participants (p<0.001), with higher levels in cirrhotic patients than controls (p<0.001). sAxl can differentiate early HCC cases from patients with cirrhosis (p<0.001). ROC curve analysis showed that sAxl has sensitivity 92.5%, specificity 93.3% and AUC 0.949 at cut off value >63.5, AFP at cut off >40.34 has sensitivity, specificity and AUC 57.5%, 60% and 0.675 respectively. The combination of AFP and sAxl at related cut off points has higher sensitivity (97.5%) and AUC 0.972 in predicting HCC in cirrhotic patients. sAxl was positively correlated with tumor size.
Conclusion: sAxl outperforms AFP in detecting HCC, especially in early HCC and in AFP-negative HCC. Combination of sAxl with AFP improved the sensitivity for early HCC diagnosis.
Keywords
HCC; cirrhosis; Alpha- fetoprotein; sAxl
Statistics
Article View: 297
PDF Download: 370